Staying on Mounjaro long term: what the evidence actually says

You've been on it six months, should you stop?

Six months in, weight loss has slowed and someone's told you that Mounjaro is only meant to be a short-term fix. It's a common thing to hear, and it isn't accurate. Tirzepatide's UK licence covers ongoing weight management alongside a reduced-calorie diet and increased physical activity, there is no 12-month or 24-month ceiling written into it, unlike the NHS guidance for Wegovy, which does carry a two-year NHS maximum.

What NICE does say, in its appraisal of tirzepatide (TA1026), is that if you haven't lost at least 5% of your starting weight after six months at the highest dose you can tolerate, continuing treatment should be reviewed. That's a sensible clinical threshold, not a blanket stop instruction. For people who are losing weight and tolerating treatment well, the guidance simply supports carrying on.

The distinction matters because weight isn't a problem you solve once. The biology that makes it harder to lose and easier to regain doesn't switch off when the scales reach a certain number. Your prescriber will be looking at whether the medicine is still working for you, whether your health has changed, and whether the benefit continues to outweigh any side effects. That conversation happens at every repeat, not just at month six.

What stopping Mounjaro actually looks like

The SURMOUNT trials (which enrolled thousands of adults across multiple studies) showed something that is now well-established in the clinical literature: when tirzepatide is stopped, a significant portion of the weight lost tends to come back over the following months. The NHS tirzepatide page reflects this too, framing it as a medicine that supports long-term weight management rather than a quick intervention.

That's not a flaw in the medicine; it's a reflection of how obesity works. The hormonal and metabolic signals that drive appetite and fat storage reassert themselves once treatment stops. This is one reason why many prescribers (and much of the clinical guidance) approach Mounjaro as a longer-term tool rather than a temporary bridge. Whether that means years rather than months is an individual question. Some people reach a stable, sustainable weight and successfully taper off with support. Others find they need ongoing treatment to maintain the gains they've made.

If you are thinking about what a longer commitment might cost, our Mounjaro price comparison page sets out the market context honestly, including what a legitimate price should include beyond just the pen.

Safety over time: what we know and what's still being studied

One of the questions people ask most is whether there are risks to taking any medicine for years rather than months. For tirzepatide, the honest answer is: the evidence base is growing but is not yet decades-long, because the medicine hasn't existed for decades. What we do have is a substantial safety dataset from the SURMOUNT and SURPASS programmes, covering thousands of participants across weight management and type 2 diabetes trials, with follow-up extending to 72 weeks or beyond.

Common side effects (nausea, loose stools, constipation, indigestion) tend to be most noticeable after starting or after a dose increase, and usually settle within a couple of weeks. They rarely arrive fresh after many months of stable dosing. More serious events such as acute pancreatitis are infrequent, but the MHRA has flagged them as something to stay alert to on any GLP-1 medicine; if you develop severe stomach pain that spreads to your back, that needs urgent medical attention, not a wait-and-see approach.

For a thorough look at what longer studies show, our page on long-term studies on Mounjaro covers the evidence in detail, and our long-term effects overview addresses specific concerns people raise. The question of whether tirzepatide has any association with certain cancers is covered separately at Mounjaro long-term effects and cancer.

In practice, the safest long-term use is supervised long-term use. A pen sitting in the fridge door month after month without a prescriber checking in on you is not what responsible treatment looks like. At nume, every repeat order triggers a fresh clinical review before anything is dispensed.

How a prescriber thinks about long-term Mounjaro treatment

When a clinician considers whether to continue prescribing tirzepatide beyond the early months, they're weighing several things: Has weight loss been meaningful and sustained? Have any weight-related conditions (blood pressure, cholesterol, blood sugar) improved? Are side effects manageable? Has anything changed in the person's medical history that affects the risk picture?

There isn't a universal answer, because there isn't a universal patient. Some people do well on a lower maintenance dose long-term. Some reach their target weight, stabilise, and work with their prescriber on a gradual withdrawal. Some need to stay at higher doses to maintain clinical benefit. What the evidence doesn't support is stopping abruptly because a fixed clock has run out.

If you're thinking about what ongoing treatment involves, or whether you'd be eligible to start, you can learn more about the Mounjaro treatment overview or explore how tirzepatide works at a mechanistic level. The question of whether long-term use is right for you is one our prescribers work through with every patient, and it starts with a free consultation. Check your eligibility to see if treatment through nume might suit you.